Leqvio Cost in Maryland 2026: Pricing, Insurance, Medicaid and Compounded Inclisiran

What Is Inclisiran (Leqvio) and Why Does Price Matter in Maryland?

Inclisiran is a small interfering RNA that silences hepatic PCSK9 synthesis, producing sustained LDL-cholesterol reductions with only two injections per year after the initial loading period. The drug is sold under the brand name Leqvio and was approved by the FDA in December 2021 for adults with primary hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), as an adjunct to maximally tolerated statins.

For Maryland patients managing atherosclerotic cardiovascular disease (ASCVD) or HeFH, inclisiran represents a real clinical advance over daily oral agents. The barrier is almost never clinical suitability. It is cost. At roughly $540 per month in list price, Leqvio sits in a price range that makes out-of-pocket cash payment impractical for most households, which is why understanding every available coverage pathway in Maryland matters before a prescriber even writes the order.

Maryland is a relatively favorable state for access. Medicaid covers the drug with prior authorization. Commercial insurers operating in the state generally place inclisiran on specialty tiers, and Novartis maintains an active patient savings program. Compounded inclisiran from 503A pharmacies has also appeared as a cash-pay option, though patients and clinicians need to understand what "legal in Maryland" actually means in that context.

Leqvio List Price vs. Real-World Cost in Maryland

The Novartis manufacturer list price for Leqvio in 2026 is approximately $540 per month, which translates to roughly $6,480 per year. Because inclisiran is dosed twice yearly after the two loading doses, a full year of therapy involves three to four clinical administrations during the first year and two thereafter. That dosing schedule does not change the list price calculation, since the price is generally quoted on a monthly basis for formulary comparison purposes.

Cash-pay prices at Maryland retail pharmacies track closely to the list price. GoodRx and similar discount programs rarely reduce specialty injectable biologics meaningfully below list, and inclisiran is no exception. The average cash-pay price across Maryland retail pharmacies in 2026 sits at approximately $540 per month with discount programs offering minimal reductions. [1]

The practical cost framework for a Maryland patient breaks into four tiers:

Tier 1. Commercially insured with savings card. Patients on employer-sponsored or individual market plans who meet Novartis eligibility criteria can use the Leqvio Savings Card to reduce their copay to as low as $0 per month. Eligibility requires that the patient is not using a government payer (Medicare, Medicaid, CHIP, TRICARE) and that their plan covers Leqvio. Patients should verify current card terms at the Novartis patient support line, since income limits and program rules may change annually.

Tier 2. Maryland Medicaid. Covered with prior authorization. Details are in the section below.

Tier 3. Medicare Part D. Inclisiran sits on specialty tiers for most Part D plans. With the Inflation Reduction Act's $2,000 out-of-pocket cap now in full effect for 2025-2026, Medicare beneficiaries face a maximum of $2 to 000 in annual drug costs regardless of drug price, which materially improves the math for high-cost injectables.

Tier 4. Compounded inclisiran. 503A compounding pharmacies in Maryland may prepare inclisiran, typically at a substantially lower cost, sometimes cited as near $0 per month on certain subscription telehealth plans. This option carries important caveats covered below.

Maryland Medicaid Coverage for Leqvio

Maryland Medicaid covers inclisiran for adults diagnosed with ASCVD or heterozygous familial hypercholesterolemia, subject to prior authorization. [2] The prior authorization criteria typically require documentation of an LDL-C above a threshold despite maximally tolerated statin therapy, a diagnosis code consistent with ASCVD or HeFH, and confirmation that the prescriber is a licensed provider with a valid Maryland DEA or NPI. Some managed care organizations (MCOs) operating within Maryland Medicaid may impose step therapy requirements, meaning the patient must have tried and had an inadequate response to high-intensity statin monotherapy before inclisiran is approved.

Maryland Medicaid is administered through a mix of fee-for-service and MCO arrangements. The specific PA form and criteria differ slightly between MCOs such as Amerigroup Maryland, CareFirst Community Health Plan, and Maryland Physicians Care. Prescribers using the HealthRX platform can request PA support through the care coordination team. Approval timelines typically run seven to fourteen days for standard review.

Maryland's Medicaid Drug Rebate Program also negotiates rebates from manufacturers, which is part of why states with active PCSK9 inhibitor coverage policies can sustain coverage despite list prices. Inclisiran's twice-yearly dosing may actually make the total drug cost lower than monthly PCSK9 antibody alternatives (alirocumab, evolocumab) for some MCOs, which may work in the patient's favor during PA review.

Clinical Evidence Supporting Inclisiran Coverage Decisions

Coverage decisions by Maryland Medicaid and commercial plans are anchored to two Phase 3 trials published in the New England Journal of Medicine in 2020.

ORION-10 enrolled 1,561 patients with ASCVD on maximally tolerated statins. Inclisiran 300 mg subcutaneous produced a placebo-adjusted LDL-C reduction of 52.3% at day 510 (P<0.001). [3] ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents. The placebo-adjusted LDL-C reduction at day 510 was 49.9% (P<0.001). [3]

The American College of Cardiology and American Heart Association 2022 Guideline on Cardiovascular Risk Reduction states: "In patients with clinical ASCVD who are on maximally tolerated statin therapy and have LDL-C levels of 70 mg/dL or higher, it is reasonable to add ezetimibe, a PCSK9 inhibitor, or inclisiran to further reduce LDL-C." [4] This guideline language is directly relevant to Maryland Medicaid PA criteria, because it establishes clinical legitimacy for inclisiran as a third-line agent after statins and ezetimibe.

Injection site reactions occurred in 2.6% of inclisiran-treated patients in ORION-10 vs. 0.9% in placebo. No clinically significant off-target effects were identified. Hepatotoxicity and myopathy signals, common concerns with older lipid agents, were not observed. [3]

Is Compounded Inclisiran Legal in Maryland?

Compounded inclisiran is available through 503A compounding pharmacies operating in Maryland. "Legal in Maryland" requires a careful reading, though.

Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), a 503A pharmacy may compound drugs that are not commercially available in the exact form needed, or that appear on FDA's drug shortage list, or that meet a patient-specific medical need documented by a licensed prescriber. Inclisiran is commercially available as Leqvio and is not currently on the FDA drug shortage list. This creates a gray zone. [5]

The FDA has not taken formal enforcement action against 503A pharmacies compounding inclisiran as of early 2026, but the agency has signaled in guidance documents that compounding commercially available drugs without a documented patient-specific need is not consistent with the statute. Maryland's Board of Pharmacy follows federal 503A standards and does not maintain a separate state prohibition, meaning a licensed Maryland 503A pharmacy may prepare compounded inclisiran when a prescriber documents a valid patient-specific rationale (for example, a documented allergy to an excipient in the branded product, or a need for a different concentration).

Patients considering compounded inclisiran should ask three questions before proceeding. First, is the pharmacy accredited by PCAB (Pharmacy Compounding Accreditation Board) or inspected by Maryland Board of Pharmacy? Second, does the prescriber document a specific clinical rationale in the chart? Third, is the active pharmaceutical ingredient (API) sourced from an FDA-registered facility?

Compounded inclisiran at 503A pharmacies in Maryland can cost significantly less than the branded product, with some telehealth platforms offering it at substantially reduced monthly rates under subscription models. The tradeoff is the absence of FDA bioequivalence review for the compounded product.

Which Insurance Plans Cover Leqvio in Maryland?

Most major commercial insurers operating in Maryland include inclisiran on their specialty tier formularies, generally with a prior authorization and sometimes with a step-edit requiring prior statin plus ezetimibe use.

CareFirst BlueCross BlueShield Maryland. Inclisiran appears on the specialty tier with PA for ASCVD and HeFH indications. Step therapy through statin plus ezetimibe applies to some plan designs.

UnitedHealthcare Maryland plans. Covered on specialty tier with PA. The Novartis savings card is accepted for commercially insured UHC members who are not on government payer programs.

Aetna Maryland. Specialty tier coverage with PA criteria aligned to ASCVD or HeFH plus inadequate LDL-C control on statins.

Maryland Medicare Advantage plans. Coverage depends on the specific plan's Part D formulary. CMS requires Part D plans to cover at least two drugs in the PCSK9 inhibitor class per formulary, though plan placement and tier may vary. Patients should use the Medicare Plan Finder tool to compare 2026 formularies before enrollment.

Employer self-insured plans. Large employer plans domiciled in Maryland are governed by ERISA and set their own formulary terms. Specialty management programs frequently require PA and sometimes a nurse case manager review for inclisiran. HR benefits administrators can check with their pharmacy benefit manager (PBM) for the specific criteria.

For any plan, the fastest route to confirming coverage is a formal prior authorization submitted by the prescriber's office, not a phone query. A formal PA generates a written decision with a right to appeal, which a phone coverage verification does not.

How the Novartis Leqvio Savings Card Works for Maryland Patients

Novartis offers a Leqvio Savings Card through its patient support program for commercially insured patients who are not enrolled in a government-funded insurance program. [6] The card can reduce the patient's out-of-pocket cost to as low as $0 per injection, though the exact benefit level and any monthly cap depend on current program terms.

To use the card in Maryland: the prescriber submits the Leqvio prescription to a specialty pharmacy that participates in the Novartis hub (such as CVS Specialty, Walgreens Specialty, or Accredo), the patient enrolls in the savings program through the Novartis One PSP hub, and the savings card is applied at the pharmacy during claim processing. Administration of inclisiran happens in the clinical setting (office or infusion center), not at home, which means the savings card may interface with both the pharmacy benefit (for the drug) and the medical benefit (for the administration). Some Maryland practices bill inclisiran under Part B for Medicare patients, in which case the savings card does not apply.

Income is not a criterion for the commercial savings card. Patients who are uninsured or underinsured may qualify instead for the Novartis Patient Assistance Program (PAP), which can provide Leqvio at no cost for eligible low-income patients who meet income and insurance criteria.

Telehealth Prescribing of Leqvio in Maryland

Inclisiran can be prescribed via telehealth in Maryland under current state law. Maryland's telehealth prescribing rules permit controlled and non-controlled prescription medications when a valid prescriber-patient relationship has been established, which can occur through a synchronous audio-video encounter. [7]

A telehealth clinician prescribing inclisiran in Maryland must still comply with all standard-of-care requirements: confirm diagnosis with documented LDL-C levels, review prior lipid therapy history, establish that the patient is on maximally tolerated statin therapy, and document medical necessity for prior authorization purposes. The drug itself is administered by subcutaneous injection in a clinical setting, so the telehealth visit handles the prescription and PA, while the patient arranges the actual injection at a local office, urgent care, or infusion center.

HealthRX offers telehealth inclisiran consultations to Maryland patients. The typical workflow involves an initial video visit, laboratory review, PA submission, and coordination with a local injecting provider or mobile phlebotomy/injection service. Wait times for injection scheduling in Maryland's major metro areas (Baltimore, Bethesda, Silver Spring, Annapolis) are generally two to four weeks after PA approval.

Comparing Inclisiran to Other PCSK9 Inhibitors on Cost in Maryland

PCSK9 inhibitors available in Maryland include alirocumab (Praluent, Sanofi/Regeneron) and evolocumab (Repatha, Amgen) in addition to inclisiran. [8] Alirocumab and evolocumab are monoclonal antibodies that require self-injection every two weeks or monthly. Inclisiran requires only two injections per year after the loading period.

List prices for alirocumab and evolocumab are similar to inclisiran in the $500-600 per month range. All three agents require PA from Maryland Medicaid and most commercial plans. The clinical differentiation for formulary purposes often comes down to patient preference for injection frequency and individual LDL response.

A 2022 cost-effectiveness analysis published in JAMA Cardiology found that inclisiran reached cost-effectiveness thresholds comparable to monthly PCSK9 antibodies primarily because of lower administration burden and projected higher adherence due to the biannual schedule. [9] Maryland Medicaid MCOs are increasingly factoring total cost of care, including adherence, into their PA criteria, which may benefit inclisiran relative to monthly injectables over a multi-year formulary horizon.

What to Do If Maryland Insurance Denies Coverage for Leqvio

Insurance denials for inclisiran in Maryland are not uncommon on first submission. The most frequent denial reasons are: failure to meet step therapy requirements (no documented trial of ezetimibe), insufficient LDL-C documentation, or administrative errors in the diagnosis code.

A step-by-step response to denial:

1. Request the denial letter in writing. Maryland law requires insurers to provide written denial with specific clinical criteria not met.
2. Have the prescriber submit a peer-to-peer review request within the plan's appeal window (typically 60 days for standard denials).
3. Supplement the PA with printed LDL-C lab values on maximally tolerated statin therapy, the ACC/AHA guideline quotation supporting inclisiran, and ORION-10/ORION-11 trial data showing the 52% LDL-C reduction at day 510.
4. If the peer-to-peer fails, file a formal internal appeal. Maryland insurers must respond to standard appeals within 30 days (or 72 hours for expedited medical appeals).
5. If the internal appeal fails, file an external review with the Maryland Insurance Administration (MIA). Maryland's external review process is independent and binding on the insurer. [10]

The success rate for external appeals in Maryland for specialty biologics is meaningful. Patients who engage an external review with clinical documentation have a real chance of reversal, particularly when the drug has an ACC/AHA guideline recommendation and the patient has documented LDL-C above target on existing therapy.

For patients who cannot wait out the appeal process, the Novartis bridge program may supply Leqvio at no cost during appeal proceedings for eligible commercially insured patients.